Masahiro Seike Selected Research

Nivolumab

8/2023	A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report.
10/2022	A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
2/2019	Eczematous reactions mimicking psoriasiform dermatitis induced by nivolumab for advanced lung cancer.
1/2019	A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency.
1/2019	Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis.
7/2017	Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masahiro Seike Research Topics

Disease

66	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 06/2003
47	Lung Neoplasms (Lung Cancer) 04/2024 - 06/2003
44	Neoplasms (Cancer) 04/2024 - 06/2003
16	Adenocarcinoma of Lung 10/2023 - 03/2006
13	Interstitial Lung Diseases (Interstitial Lung Disease) 06/2024 - 07/2016
13	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2024 - 06/2003
12	Adenocarcinoma 01/2020 - 06/2003
9	Neoplasm Metastasis (Metastasis) 12/2023 - 06/2003
6	Carcinogenesis 01/2023 - 08/2003
5	Fever (Fevers) 06/2024 - 05/2018
5	Brain Neoplasms (Brain Tumor) 04/2024 - 01/2020
5	Disease Progression 02/2024 - 05/2018
5	COVID-19 11/2022 - 01/2022
5	Pneumonia (Pneumonitis) 01/2022 - 07/2017
5	Idiopathic Pulmonary Fibrosis 09/2021 - 04/2011
5	Xanthomatosis (Xanthoma) 03/2007 - 12/2002
4	Chronic Obstructive Pulmonary Disease (COPD) 02/2024 - 03/2016
4	Dyspnea (Shortness of Breath) 01/2023 - 07/2017
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2016 - 07/2005
3	Respiratory Insufficiency (Respiratory Failure) 02/2024 - 12/2021
3	Pleural Effusion (Pleural Effusions) 09/2022 - 02/2013
3	Organizing Pneumonia 01/2022 - 01/2019
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2021 - 07/2016
3	Idiopathic Interstitial Pneumonias 12/2019 - 01/2011
3	Malignant Mesothelioma 02/2019 - 06/2014
3	Dermatitis 02/2019 - 10/2006
2	Anemia 06/2024 - 01/2023
2	Granuloma 01/2023 - 07/2017
2	Cough 01/2023 - 07/2017
2	Febrile Neutropenia 10/2022 - 12/2021
2	Weight Loss (Weight Reduction) 04/2022 - 01/2022
2	Vomiting 04/2022 - 01/2016
2	Fibrosis (Cirrhosis) 01/2021 - 07/2020
2	Mesothelioma 01/2021 - 01/2018
2	Malignant Pleural Effusion 01/2020 - 02/2013
2	Hemorrhage 12/2019 - 01/2018
2	Nausea 01/2019 - 01/2016
2	Carcinoma (Carcinomatosis) 11/2018 - 07/2009

Drug/Important Bio-Agent (IBA)

17	Tyrosine Kinase InhibitorsIBA 12/2023 - 11/2007
17	Proteins (Proteins, Gene)FDA Link 01/2023 - 08/2003
16	Carboplatin (JM8)FDA LinkGeneric 08/2023 - 06/2006
15	ErbB Receptors (EGF Receptor)IBA 12/2023 - 11/2007
13	osimertinibIBA 04/2024 - 01/2018
13	Biomarkers (Surrogate Marker)IBA 01/2024 - 12/2006
9	MicroRNAs (MicroRNA)IBA 03/2023 - 03/2006
9	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 04/2004
9	pembrolizumabIBA 01/2023 - 01/2018
8	Immune Checkpoint InhibitorsIBA 09/2023 - 01/2020
8	B7-H1 AntigenIBA 08/2023 - 01/2018
8	Gefitinib (Iressa)FDA Link 11/2022 - 12/2006
7	Paclitaxel (Taxol)FDA LinkGeneric 08/2023 - 06/2006
7	Anaplastic Lymphoma KinaseIBA 01/2023 - 05/2013
7	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 07/2016
6	Pemetrexed (MTA)FDA Link 11/2023 - 06/2014
6	NivolumabIBA 08/2023 - 07/2017
5	LigandsIBA 03/2023 - 12/2006
5	Bevacizumab (Avastin)FDA Link 01/2023 - 02/2013
4	alectinibIBA 01/2023 - 01/2017
4	PlatinumIBA 01/2023 - 01/2021
4	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2023 - 05/2012
4	130-nm albumin-bound paclitaxelIBA 01/2023 - 12/2021
4	Docetaxel (Taxotere)FDA Link 10/2022 - 06/2006
4	RNA (Ribonucleic Acid)IBA 01/2022 - 11/2003
4	Histamine (Histamine Dihydrochloride)FDA Link 01/2017 - 08/2005
4	Histone Deacetylase InhibitorsIBA 06/2010 - 11/2007
4	oxidized low density lipoproteinIBA 03/2007 - 12/2002
4	LDL Lipoproteins (beta Lipoproteins)IBA 03/2007 - 12/2002
3	SteroidsIBA 11/2023 - 11/2018
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2023 - 02/2013
3	amrubicinIBA 07/2023 - 03/2013
3	AntibodiesIBA 06/2023 - 01/2020
3	Oxygen (Dioxygen)IBA 08/2022 - 01/2021
3	Albumin-Bound Paclitaxel FDA Link 04/2022 - 02/2019
3	SolutionsIBA 03/2022 - 01/2018
3	AfatinibIBA 04/2021 - 10/2018
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2021 - 09/2012
3	Monoclonal AntibodiesIBA 01/2019 - 07/2017
3	Irinotecan (Camptosar)FDA LinkGeneric 03/2013 - 04/2004
3	Messenger RNA (mRNA)IBA 06/2010 - 11/2003
3	DNA (Deoxyribonucleic Acid)IBA 01/2010 - 11/2003
2	Anti-Bacterial Agents (Antibiotics)IBA 06/2024 - 01/2022
2	TOR Serine-Threonine KinasesIBA 01/2024 - 04/2015
2	durvalumabIBA 11/2023 - 09/2023
2	Polysaccharides (Glycans)IBA 10/2023 - 01/2023
2	FucoseIBA 10/2023 - 01/2023
2	nintedanibIBA 01/2023 - 03/2016
2	Gemcitabine FDA Link 01/2023 - 06/2006
2	CytokinesIBA 08/2022 - 08/2007
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022 - 11/2012
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 07/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 05/2018 - 01/2016

Therapy/Procedure

39	Therapeutics 02/2024 - 06/2003
26	Drug Therapy (Chemotherapy) 04/2024 - 01/2011
4	Chemoradiotherapy 11/2023 - 01/2020
4	Combination Drug Therapy (Combination Chemotherapy) 08/2023 - 10/2012
4	Aftercare (After-Treatment) 09/2022 - 04/2015
3	Radiotherapy 04/2024 - 04/2011
3	Immunotherapy 04/2024 - 01/2018
2	Adjuvant Chemotherapy 09/2022 - 03/2022
2	Pleurodesis 01/2020 - 02/2013